FDA
-
-
-
-
-
-
-
DEINOVE: DNV3837 Antibiotic Candidate: the Phase II Trial Continues in the United States, Despite a Disrupted Context Due to The COVID-19 Outbreak
-
-
-
-
-
-
-
2019 Half-year consolidated results: Deinove’s progress coming to fruition
-
-
-
-
-
-
-
Deinove : General meeting of May 23: Shareholders approve the acquisition of MORPHOCHEM
-
-
-
-
-
323,761 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

